| First Author | Lian J | Year | 2018 |
| Journal | Biochim Biophys Acta Mol Cell Biol Lipids | Volume | 1863 |
| Issue | 7 | Pages | 688-699 |
| PubMed ID | 29631096 | Mgi Jnum | J:265855 |
| Mgi Id | MGI:6199776 | Doi | 10.1016/j.bbalip.2018.04.002 |
| Citation | Lian J, et al. (2018) Genetic variation in human carboxylesterase CES1 confers resistance to hepatic steatosis. Biochim Biophys Acta Mol Cell Biol Lipids 1863(7):688-699 |
| abstractText | Obesity often leads non-alcoholic fatty liver disease, insulin resistance and hyperlipidemia. Expression of carboxylesterase CES1 is positively correlated with increased lipid storage and plasma lipid concentration. Here we investigated structural and metabolic consequences of a single nucleotide polymorphism in CES1 gene that results in p.Gly143Glu amino acid substitution. We generated a humanized mouse model expressing CES1(WT) (control), CES1(G143E) and catalytically dead CES1(S221A) (negative control) in the liver in the absence of endogenous expression of the mouse orthologous gene. We show that the CES1(G143E) variant exhibits only 20% of the wild-type lipolytic activity. High-fat diet fed mice expressing CES1(G143E) had reduced liver and plasma triacylglycerol levels. The mechanism by which decreased CES1 activity exerts this hypolipidemic phenotype was determined to include decreased very-low density lipoprotein secretion, decreased expression of hepatic lipogenic genes and increased fatty acid oxidation as determined by increased plasma ketone bodies and hepatic mitochondrial electron transport chain protein abundance. We conclude that attenuation of human CES1 activity provides a beneficial effect on hepatic lipid metabolism. These studies also suggest that CES1 is a potential therapeutic target for non-alcoholic fatty liver disease management. |
